ProShares UltraShort NASDAQ Biotechnology
6 hedge funds and large institutions have $385K invested in ProShares UltraShort NASDAQ Biotechnology in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 6 → 6 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
6.42% less ownership
Funds ownership: 12.21% → 5.79% (-6.4%)
55% less capital invested
Capital invested by funds: $859K → $385K (-$473K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$316K |
| 2 |
Simplex Trading
Chicago,
Illinois
|
+$1.27K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IMC Chicago
Chicago,
Illinois
|
-$443K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$187K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$130K |
| 4 |
Morgan Stanley
New York
|
-$1.6K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$218 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $289K | +$316K | +8,680 | New |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $92.6K | -$130K | -3,582 | -56% |
|
3
Citigroup
New York
| $1.42K | – | – | – |
|
|
4
Morgan Stanley
New York
| $1.25K | -$1.6K | -44 | -54% |
|
|
5
Simplex Trading
Chicago,
Illinois
| $1K | +$1.27K | +35 | New |
|
|
6
UBS Group
Zurich,
Switzerland
| $17 | -$218 | -6 | -86% |
|
|
7
IMC Chicago
Chicago,
Illinois
| – | -$443K | -12,605 | Closed |
|
|
8
Citadel Advisors
Miami,
Florida
| – | -$187K | -5,325 | Closed |
|
BIS Hedge Fund Activity: Q2 2024 in Review
6 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q2 2024, worth a combined $385K — down 55% from $859K a quarter earlier.
Fund positioning in BIS was balanced in Q2 2024: 2 funds opened new positions, 2 closed out, 0 added to existing stakes and 3 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $316K. The largest seller was IMC Chicago, exiting entirely with an estimated $443K sold.
- 6 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $385K of ProShares UltraShort NASDAQ Biotechnology stock for Q2 2024, down 55% quarter-over-quarter.
- 2 funds opened new ProShares UltraShort NASDAQ Biotechnology positions in Q2 2024 and 2 closed out, a net change of 0 holders.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q2 2024 was Susquehanna International Group, an estimated $316K added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q2 2024 was IMC Chicago, an estimated $443K sold.
Based on aggregated 13F filings for Q2 2024.